Epicutaneous immunotherapy for peanut allergy found safe, tolerable through 5 years

Treatment-emergent adverse events with epicutaneous immunotherapy for peanut allergy grew less frequent and severe over 5 years, according to a poster at the American Academy of Allergy, Asthma & Immunology Annual Meeting.